Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Busy address KBO
21 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
Newton Biocapital I, pricaf privée de droit belge from Sint-Pieters-Woluwe, company number BE0674831275, closed financial year 2025 with a result of € -5.3 million after tax. For that financial year Newton Biocapital I, pricaf privée de droit belge recorded a gross margin of € -1.4 million and equity of € 59.5 million. Compared with financial year 2024, the result moved from € -18.7 million to € -5.3 million. The company made a loss. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 1, 2026.
€ 59.5 million
▲ 1% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -5.3 million
▲ 72 % less loss than in 2024
Profit after tax over the fiscal year.
€ 496,235
▲ 84% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -40.4 million.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 13,839
▼ 70% vs 2024
Supplier invoices still open on the last day of the fiscal year.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € -2,441,449 | € -1,788,138 | € -1,803,639 | € -1,431,228 | ▲ € 372,411 |
| Profit after taxes | € -3,437,508 | € 909,317 | € -18,721,216 | € -5,322,668 | ▲ € 13.4 million |
| Equity | € 65,496,942 | € 71,731,174 | € 58,691,810 | € 59,462,181 | ▲ 1% |
| Total debts | € 77,703 | € 63,857 | € 77,050 | € 45,683 | ▼ 41% |
| Cash | € 7,809,370 | € 5,849,923 | € 270,300 | € 496,235 | ▲ 84% |
| Retained profit | € -17,299,384 | € -16,390,067 | € -35,111,283 | € -40,433,951 | ▼ € 5.3 million |
| Balance sheet total | € 65,574,645 | € 71,795,031 | € 58,768,860 | € 59,507,864 | ▲ 1% |
Key figures of Newton Biocapital I, pricaf privée de droit belge, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Newton Biocapital I, pricaf privée de droit belge?
What happened at Newton Biocapital I, pricaf privée de droit belge in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- JCO CONSULTING SRL stepped down as director. NBB
- DAB MANAGEMENT SRL stepped down as director. NBB
- SPARAXIS SA stepped down as director. NBB
- Michihiko WADA stepped down as director. NBB
- SUNATHIM SRL stepped down as director. NBB
- SFPIM SA DP stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 5.3 million. Source: NBB ↗
- Christophe DEMAIN stepped down as director. NBB
In short
From € 3.4 million loss in 2022 to € 5.3 million loss in 2025.
Best year ever: 2023, with € 909,317 profit.
Management
The stake of FEDERALE PARTICIPATIE- EN INVESTERINGSMAATSCHAPPIJ, SOCIETE WALLONNE POUR LE FINANCEMENT DES INFRASTUCTURES DES POLES DE COMPETITIVITES, Newton Biocapital I Investment Pool, INVESTSUD TECH, INVESTSUD, Affix Corporate Finance comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
Newton Biocapital I, pricaf privée de droit belgeBehind Newton Biocapital I, pricaf privée de droit belge is NEWTON BIOCAPITAL PARTNERS SRL. The shares are held by FEDERALE PARTICIPATIE- EN INVESTERINGSMAATSCHAPPIJ (17.7%), SOCIETE WALLONNE POUR LE FINANCEMENT DES INFRASTUCTURES DES POLES DE COMPETITIVITES (17.6%), Newton Biocapital I Investment Pool (4.6%), INVESTSUD TECH (2.6%), INVESTSUD (0.1%) and Affix Corporate Finance (0%). It owns 69.6% of DEUTERONCOLOGY, 36.2% of DIM3 - En liquidation, 30.3% of PRISM BIOLAB, 25.7% of ABOLERIS HOLDCO, 25.5% of NEUVASQ BIOTECHNOLOGIES and 24.4% of EPICS THERAPEUTICS itself.
Directors
According to the 2025 annual accounts
NEWTON BIOCAPITAL PARTNERS SRL
Personne déléguée à la gestion journalière · represented by Alain PARTHOENS
Also active at: SYNERGIA MEDICAL, Newton Biocapital I Investment Pool, EPICS THERAPEUTICS, DeuterOncology, NEUVASQ BIOTECHNOLOGIES, Aboleris Holdco, FLANDERSBIO
since 2017
Director · represented by Jean Combalbert
Also active at: EPICS THERAPEUTICS, THERAtRAME
since 2025 · until 2027
Director · represented by Dirk BOOGMANS
Also active at: C.S.M., ENERGY SOLUTIONS GROUP, Smile Invest Management Company, Newton Biocapital II, ALINSO GROUP, HELIOS Foundation
since 2024 · until 2027
Director · represented by Sophie SAUVAGE
Also active at: C.P. Bourg, A.M.B., Jean Goldschmidt International, Ateliers Pierre Cerfontaine, Floridienne, Fonderies J. Marichal Ketin et Cie, JUNGLING, MEBF +224 more
since 2024 · until 2027
Michihiko WADA
Director
since 2024 · until 2027
Director · represented by Ajit SHETTY
Also active at: SOUDAL HOLDING, reMYND, REJUVENATE BIOMED, Newton Biocapital II
since 2024 · until 2027
Christophe DEMAIN
Director
since 2021 · until 2025
Director · represented by François FONTAINE
Also active at: Aviapartner Belgium, Société Anonyme Belge de Constructions Aéronautiques, Société Nationale de Construction Aérospatiale, COMETSAMBRE, ASCO INDUSTRIES, ZEPHYR - FIN, Sabena Aerospace Engineering, reMYND +58 more
since 2024 · until 2027
Robert HIRST
Director
since 2024 · until 2025
Shareholders
Participations
69.6%
36.2%
PRISM BIOLAB
30.3%
25.7%
25.5%
24.4%
21.9%
EDITFORCE INC
19.1%
14.6%
J-PHARMA (A été côtée le 25-03-2026)
8.3%
3.9%
Establishments
Establishment units
Physical locations of this company
Tervurenlaan 273
1150 Sint-Pieters-Woluwe
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 21 companies are registered at this address.
All companies at this address →BELGIAN RISK MANAGEMENT ASSOCIATION
European Coil Coating Association
€ 877,191 revenue · 2025
FEDERATION EUROPEENNE DE RISK MANAGEMENT - FEDERATION OF EUROPEAN RISK MANAGEMENT ASSOCIATIONS
€ 3.2 million revenue · 2024
LATOUR & PETIT
€ 1.5 million gross margin · 2025
AQ PARTNERS
€ 69,850 gross margin · 2025
+16 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0674.831.275
- VAT number
- BE 0674.831.275
- Registered office
- Tervurenlaan 273, 1150 Sint-Pieters-Woluwe
- Names & denominations
- Newton Biocapital I, pricaf privée de droit belge
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 25 April 2017
- Peppol
- Active · Active since 21 Oct 2026